The primary objective of this trial is to investigate the safety and tolerability of BI 456906 in healthy subjects following single rising doses. The secondary objective is the exploration of the pharmacokinetics including dose proportionality, and pharmacodynamics (PD) of BI 456906 after single dosing
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
20
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
[N (%)] of subjects with drug-related adverse events.
Time frame: Up to 672 hours
AUC0-168 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 168h)
Time frame: up to 168 hours
Cmax (maximum measured concentration of the analyte in plasma)
Time frame: up to 672 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.